Mark A. Velleca - Jun 15, 2021 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role
Director
Signature
/s/ James Stillman Hanson, attorney-in-fact
Stock symbol
GTHX
Transactions as of
Jun 15, 2021
Transactions value $
-$647,321
Form type
4
Date filed
6/17/2021, 04:05 PM
Previous filing
May 25, 2021
Next filing
Jul 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $3.9K +10K +16.39% $0.39* 71K Jun 15, 2021 Direct
transaction GTHX Common Stock Sale -$224K -10K -14.08% $22.39* 61K Jun 15, 2021 Direct F1, F2
transaction GTHX Common Stock Options Exercise $3.9K +10K +16.39% $0.39* 71K Jun 16, 2021 Direct
transaction GTHX Common Stock Sale -$217K -10K -14.08% $21.74* 61K Jun 16, 2021 Direct F1, F3
transaction GTHX Common Stock Options Exercise $3.9K +10K +16.39% $0.39* 71K Jun 17, 2021 Direct
transaction GTHX Common Stock Sale -$218K -10K -14.08% $21.77* 61K Jun 17, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10K -3.48% $0.00 277K Jun 15, 2021 Common Stock 10K $0.39 Direct F5
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10K -3.61% $0.00 267K Jun 16, 2021 Common Stock 10K $0.39 Direct F5
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10K -3.74% $0.00 257K Jun 17, 2021 Common Stock 10K $0.39 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price represents the weighted average price with a low of $22.10 and a high of $22.64. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
F3 The price represents the weighted average price with a low of $21.55 and a high of $21.87. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
F4 The price represents the weighted average price with a low of $21.44 and a high of $21.92. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.
F5 All shares underlying this option have vested.